Molgramostim
As of the edition of 20 October 2026, Molgramostim is a protein: marketed; acts on CSF3R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Protein
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Labo'life España S.A.U
- Registered trials
- 10, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Heart and blood vessels; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | Q99062 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 4 | 2 | 0 | 0 |
| Phase 3 | 3 | 0 | 2 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Savara | Lead sponsor of trials | 2015 to now |
| Reponex Pharmaceuticals A/S | Lead sponsor of trials | 2021 to now |